Levonorgestrel and Ethinyl Estradiol Tablets, USP 0.15 mg/0.03 mg

back to all products
Chateal® is an AB-Rated generic oral contraceptive

Reference Drug: Levora®

Compares to: Portia®, Altavera®, Marlissa® and Kurvelo ®
  • Single-phase continuous administration regimen
    • 21 white to off-white tablets of levonorgestrel and ethinyl estradiol
    • 7 green non-hormone containing tablets to help ease administration
    • Combined in a 28-day tablet blister pack
Product Gallery
ndc # package size pi order numbers
50102-130-03 Carton Containing
3 Packages

ORDER Chateal®




1-800-331-2632 (Ext. 74591)



R&S Northeast


Seacoast Medical LLC


Smith Medical Partners LLC

340B 1-877-445-7970


Indication and Usage of Chateal®

Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases.


INDICATIONS AND USAGE Oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.


Combination oral contraceptives should not be used in women with any of the following conditions:

  • Thrombophlebitis or thromboembolic disorders.
  • A past history of deep-vein thrombophlebitis or thromboembolic disorders.
  • Cerebral-vascular or coronary artery disease.
  • Thrombogenic valvulopathies.
  • Thrombogenic rhythm disorders.
  • Uncontrolled hypertension.
  • Diabetes with vascular involvement.
  • Known or suspected carcinoma of the breast.
  • Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia.
  • Undiagnosed abnormal genital bleeding.
  • Cholestatic jaundice of pregnancy or jaundice with prior pill use.
  • Hepatic adenomas or carcinomas, or active liver disease, as long as liver function has not returned to normal.
  • Known or suspected pregnancy.
  • Hypersensitivity to any component of CHATEAL (levonorgestrel and ethinyl estradiol tablets, USP).
  • Are receiving Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations.

Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with the extent of smoking (in epidemiologic studies, 15 or more cigarettes per day was associated with a significantly increased risk) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.


The use of oral contraceptives is associated with increased risks of several serious conditions including venous and arterial thrombotic and thromboembolic events (such as myocardial infarction, thromboembolism, and stroke), hepatic neoplasia, gallbladder disease, and hypertension, although the risk of serious morbidity or mortality is very small in healthy women without underlying risk factors. The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as certain inherited or acquired thrombophilias, hypertension, hyperlipidemias, obesity, diabetes, and surgery or trauma with increased risk of thrombosis. Practitioners prescribing oral contraceptives should be familiar with information relating to these risks.

Risk information described in the full Prescribing Information includes:

  1. Thromboembolic Disorders and Other Vascular Problems
  2. Estimates of Mortality from Contraceptive Use
  3. Carcinoma of the Reproductive Organs and Breasts
  4. Hepatic Neoplasia
  5. Use in women receiving Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations
  6. Ocular Lesions
  7. Oral Contraceptive Use Before or During Early Pregnancy
  8. Gallbladder Disease
  9. Carbohydrate and Lipid Metabolic Effects
  10. Elevated Blood Pressure
  11. Headache
  12. Bleeding Irregularities


The most serious reactions are discussed in detail in the full product labeling and include serious cardiovascular events and smoking, vascular events and liver disease. Commonly reported adverse reactions include irregular uterine bleeding, nausea, breast tenderness and headache.

Combination oral contraceptives, including Chateal, should not be used in women with any of the following conditions:


To achieve maximum contraceptive effectiveness, CHATEAL must be taken exactly as directed and at intervals not more than 24 hours apart.

Reference: Chateal® prescribing information, Charleston SC USA, August 2017
Please see full prescribing information here.

To report SUSPECTED ADVERSE REACTIONS, call 1-855-888-2467 or report via the FDA MedWatch Program at or 1-800-FDA-1088.